ICON PLC (ICLR)vsNatera Inc (NTRA)
ICLR
ICON PLC
$169.31
+2.18%
HEALTHCARE · Cap: $12.22B
NTRA
Natera Inc
$328.93
+0.86%
HEALTHCARE · Cap: $46.72B
Smart Verdict
WallStSmart Research — data-driven comparison
ICON PLC generates 206% more annual revenue ($8.29B vs $2.71B). ICLR leads profitability with a 0.3% profit margin vs -7.1%. ICLR earns a higher WallStSmart Score of 51/100 (C-).
ICLR
Buy51
out of 100
Grade: C-
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+61.0%
Fair Value
$341.51
Current Price
$169.31
$172.20 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
1.2% revenue growth
Distress zone — elevated risk
ROE of 0.7% — below average capital efficiency
0.3% margin — thin
0.0% earnings growth
Weak financial health signals
Trading at 25.9x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ICLR
The strongest argument for ICLR centers on PEG Ratio, Price/Book. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : ICLR
The primary concerns for ICLR are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 247.4x leaves little room for execution misses. Thin 0.3% margins leave little buffer for downturns.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
ICLR profiles as a value stock while NTRA is a hypergrowth play — different risk/reward profiles.
NTRA carries more volatility with a beta of 1.53 — expect wider price swings.
NTRA is growing revenue faster at 37.7% — sustainability is the question.
ICLR generates stronger free cash flow (235M), providing more financial flexibility.
Bottom Line
ICLR scores higher overall (51/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ICON PLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
ICON Public Limited Company, a clinical research organization, provides outsourced marketing and development services in Ireland, the rest of Europe, the United States and internationally. The company is headquartered in Dublin, Ireland.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?